Company Dosed First Phase 2 Mild Alzheimer’s Disease Patient with Xpro1595; Presented Data from Ongoing INKmune™ Studies Suggesting Increased NK Cell Treatment Effective Against Solid Malignancies

$66.7 Million in cash as of March 31, 2022

Company to Host Conference Call Today, May 5, at 4:30pm ET

BOCA RATON, FL., May 05, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported its financial results for the quarter ended March 31, 2022 and provided a business update.

Q1 2022 and Recent Corporate Highlights

DN-TNF Platform Highlights (XPro™ and INB03):

  • Dosed the first patient in the Phase II trial using XPro™ to treat patients with mild Alzheimer’s Disease (AD). The primary endpoint will examine cognition using the Early AD/MCI Alzheimer's Cognitive Composite (EMACC). Data is anticipated in the second half of 2023.
  • Delivered multiple oral and poster presentations at AD/PD 2022 (International Conference on Alzheimer’s and Parkinson’s Disease).
  • Presented breast cancer data at the 2022 American Association for Cancer Research (AACR) Annual Meeting, which suggested the use of INmune Bio’s DN-TNF candidate, INB03, may help reverse resistance to immunotherapy patients with HER2+ cancers.

INKmune™ Platform Highlights:

  • Planned expansion of INKmune program to include AML and new site in EU.
  • 2 of 3 patients with MDS/AML remain stable more than 6 months after the last treatment with INKmune.
  • INKmune shows best-in-class therapeutic persistence measured by activated tumor killing NK cells (NKG2D+ NK cells) in the peripheral blood or bone marrow more than 100 days after INKmune™ treatment in the two patients with stable disease
  • Highlighted the potential of INKmune primed NK cells to treat solid tumors by improving the ability of natural killer (NK) cells to survive hostile tumor microenvironments and by increased avidity, a necessary step for cancer cell killing, compared to NK cells primed with cytokines (IL-2, IL15).   

Upcoming Milestones:

  • Initiate Xpro™ Phase 2 program for Mild Cognitive Impairment (MCI) in patients 1H 2022.
  • Initiate XPro™ Phase 2 program for treatment resistant depression (TRD), funded in part by a $2.9 million NIH grant, by 2H 2022.
  • Continued enrollment and opening of sites for XPro™ Phase 2 program for mild AD.
  • Initiate INKmune™ Phase 1 program in ovarian cancer or solid tumor in 2H 2022.
  • Additional open-label Phase 1 trial data of INKmune™ in high-risk MDS/AML.
  • Report top-line data from Phase 2 trial of Xpro™ in MCI patients in mid-2023.
  • Report top-line data from Phase 2 trial of XPro™ in Mild AD patients in 2H 2023.
  • Report pre-clinical INKmune™ data in renal cell carcinoma and nasopharyngeal carcinoma.

“Our scientific platforms continue to showcase our unique approach to repairing dysfunction of the innate immune system,” stated RJ Tesi, M.D., CEO of INmune Bio. “In April, we announced the dosing of our first patient treated with XPro1595 (“XPro™) in the treatment of neuroinflammation as a cause of mild Alzheimer’s disease (AD) in a Phase II clinical trial AD02, a blinded, randomized, placebo-controlled multicenter study in Australia, in Canada and in the United States that will assess the cognitive and functional impact of XPro™ in 201 mild AD patients. A second blinded, randomized, placebo-controlled Phase 2 trial in patients with mild cognitive impairment (MCI) is also planned. It appears that targeting amyloid and tau have little therapeutic benefit. Newer treatment strategies such as targeting glial dysfunction with XPro™ is supported by pre-clinical and epidemiologic studies. We expect top-line results from both clinical trials in 2023.”

“The impact of inflammation and in particular TNF is increasingly apparent as evinced by recent genetic (link) studies,” stated CJ Barnum, VP of CNS Development at INmune Bio. “These Phase 2 studies are the first step in determining the extent to which neutralizing solTNF will benefit MCI and AD patients. Our expectations are high, and we look forward to sharing the results next year.

“The clinical and scientific framework around INKmune™, our NK cell targeting platform continues to grow. We have already observed that two of the three patients treated with INKmune™ for MDS/AML remain off therapy with their disease controlled for more than 6 months since their last dose of INKmune™,” said Dr. Mark Lowdell, Chief Scientific Officer of INmune Bio. “We are demonstrating the effectiveness of INKmune™ in treatment of hematologic malignancies but believe the most promising application will be using INKmune™ to treat residual disease in solid tumors.”

“Separately, we presented additional pre-clinical breast cancer data at the American Association for Cancer Research (AACR) Annual Meeting 2022, which further demonstrated the use of our DN-TNF oncology drug candidate, INB03, to potentially help reverse resistance to immunotherapy for women with HER2+ breast cancer. With this robust collection of data in multiple indications, we are optimistic for the coming quarters and look forward to sharing our continued results with shareholders and clinicians alike,” stated Dr. Tesi.

“We continue to move forward on our planned three Phase II programs this year and believe we are well positioned to deliver on potential value creating milestones in both our DN-TNF and INKmune™ platforms,” concluded Dr. Tesi.

Financial Results for the Quarter Ended March 31, 2022:

Net loss attributable to common stockholders for the quarter ended March 31, 2022 was approximately $6.9 million, compared to approximately $4.6 million for the quarter ended March 31, 2021.

Revenues totaled approximately $0.2 million for the first quarter 2022 compared to approximately $0.0 million for the first quarter 2021.

Research and development expense totaled approximately $4.3 million for the first quarter 2022 compared to approximately $2.5 million during the first quarter 2021.

General and administrative expense was approximately $2.3 million for the first quarter 2022 compared to approximately $2.1 million during the first quarter 2021.

Other expense was approximately $0.4 million for the first quarter 2022 compared to approximately $0.0 million during the first quarter 2021.

As of March 31, 2022, the Company had cash and cash equivalents of approximately $66.7 million.

During the quarter, RJ Tesi, Mark Lowdell, David Moss and Kelly Ganjei bought 82,900 shares for approximately $700,000 as previously reported in an 8-K filed with the SEC. As of May 5, 2022, the Company had approximately 17.9 million common shares outstanding.

Earnings Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

Date: May 5, 2022
Time: 4:30 PM Eastern Time
Participant Dial-in: 1-877-407-0784
Participant Dial-in (international): 1-201-689-8560
Conference ID: 13728543

A live audio webcast of the call can be accessed using this link:

A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through May 12, 2022 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 13728543.

About XPro™

XPro™ is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trial and acts differently than currently available TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro™ could have potential substantial beneficial effects in patients with neurologic disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website.

About INKmune™

INKmune™ is a pharmaceutical-grade, replication-incompetent human tumor cell line which conjugates to resting NK cells and delivers multiple, essential priming signals akin to treatment with at least three cytokines in combination. INKmune™ is stable at -80oC and is delivered by a simple IV infusion. The INKmune:NK interaction ligates multiple activating and co-stimulatory molecules on the NK cell and enhances its avidity of binding to tumor cells; notably those resistant to normal NK-mediated lysis. Tumor-primed NK (TpNK) cells can lyse a wide variety of NK-resistant tumors including leukemias, lymphomas, myeloma, ovarian cancer, breast cancer.

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit

Forward Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact:

David Moss, CFO (858) 964-3720
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Contact: Jason Nelson
Core IR
(516) 842-9614 x-823

The following table summarizes our results of operations for the periods indicated:


(In thousands, except share and per share amounts)

  March 31,     December 31,  
  2022     2021  
CURRENT ASSETS              
Cash and cash equivalents $ 66,729     $ 74,810  
Research and development tax credit receivable   5,149       4,913  
Other tax receivable   499       591  
Prepaid expenses   4,668       2,278  
Prepaid expenses – related party   14       14  
TOTAL CURRENT ASSETS   77,059       82,606  
Operating lease – right of use asset – related party   681       726  
Other assets   99       99  
Acquired in-process research and development intangible assets   16,514       16,514  
TOTAL ASSETS $ 94,353     $ 99,945  
Accounts payable and accrued liabilities $ 2,551     $ 3,733  
Accounts payable and accrued liabilities – related parties   9       80  
Deferred liabilities   584       474  
Operating lease, current liabilities   82       72  
TOTAL CURRENT LIABILITIES   3,226       4,359  
Long-term debt, less debt discount   14,514       14,458  
Long-term operating lease liabilities   684       704  
Accrued liability – long-term   287       199  
TOTAL LIABILITIES   18,711       19,720  
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding   -       -  
Common stock, $0.001 par value, 200,000,000 shares authorized, 17,945,995 and 17,843,303 shares issued and outstanding, respectively   18       18  
Additional paid-in capital   146,186       143,921  
Accumulated other comprehensive income   56       1  
Accumulated deficit   (70,618 )     (63,715 )
TOTAL STOCKHOLDERS’ EQUITY   75,642       80,225  


(In thousands, except share and per share amounts)

  Three months ended  
  March 31,  
  2022     2021  
REVENUE $ 163     $ 4  
General and administrative   2,332       2,061  
Research and development   4,309       2,491  
Total operating expenses   6,641       4,552  
LOSS FROM OPERATIONS   (6,478 )     (4,548 )
OTHER EXPENSE              
Other expense, net   (425 )     (8 )
Total other expense, net   (425 )     (8 )
NET LOSS $ (6,903 )   $ (4,556 )
Net loss per common share – basic and diluted $ (0.39 )   $ (0.32 )
Weighted average number of common shares outstanding – basic and diluted   17,870,285       14,322,659  
Net loss $ (6,903 )   $ (4,556 )
Other comprehensive income  – foreign currency translation   55       1  
Total comprehensive loss $ (6,848 )   $ (4,555 )


(In thousands)

  For the Three Months  
  Ended March 31,  
  2022     2021  
Net loss $ (6,903 )   $ (4,556 )
Adjustments to reconcile net loss to net cash used in operating activities:              
Stock-based compensation   1,536       899  
Accretion of debt discount   56       -  
Changes in operating assets and liabilities:              
Research and development tax credit receivable   (236 )     (504 )
Other tax receivable   92       (41 )
Prepaid expenses   (2,390 )     (1,294 )
Prepaid expenses – related party   -       (15 )
Accounts payable and accrued liabilities   (1,182     54  
Accounts payable and accrued liabilities – related parties   (71 )     (24 )
Deferred liabilities   110       401  
Accrued liability – long-term   88       -  
Operating lease liabilities   35       (12 )
Net cash used in operating activities   (8,865 )     (5,092 )
Net proceeds from sale of common stock   699       28,446  
Net proceeds from the exercise of warrants   30       18  
Net cash provided by financing activities   729       28,464  
Impact on cash from foreign currency translation   55       1  
NET (DECREASE) INCREASE IN CASH   (8,081 )     23,373  
Cash paid for income taxes $ -     $ -  
Cash paid for interest expense $ 291     $ -  

This website uses cookies to facilitate the use of the website, improve its performance and security, and personalize the proposed content.